section name header

Pronunciation

ne-VEER-a-peen audio

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: non nucleoside reverse transcriptase inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: >90% absorbed after oral administration.

Distribution: Crosses placenta and enters breast milk; CSF levels are 45% of those in plasma.

Metabolism/Excretion: Mostly metabolized by the liver (CYP3A4 enzyme system); minor amounts excreted unchanged in urine.

Half-life: 25–30 hr (during multiple dosing).

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
PO-IRrapid4 hr12 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Reflects combination therapy

Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), rash (may progress to toxic epidermal necrolysis), STEVENS-JOHNSON SYNDROME.

GI: HEPATOTOXICITY, liver enzymes, nausea, abdominal pain, diarrhea, hepatitis, ulcerative stomatitis.

GU: fertility (females).

Hemat: granulocytopenia ( in children).

MS: myalgia.

Neuro: paresthesia, peripheral neuropathy , headache.

Misc: fever, immune reconstitution syndrome.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

see Calculator

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Viramune, Viramune XR

Pot. Nursing Diagnoses

Code

NDC Code*